Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy and Safety of Fast-acting Insulin Aspart Compared to NovoRapid Both in Combination With Insulin Degludec With or Without Metformin in Adults With Type 2 Diabetes (Onset 9)

Trial Profile

Efficacy and Safety of Fast-acting Insulin Aspart Compared to NovoRapid Both in Combination With Insulin Degludec With or Without Metformin in Adults With Type 2 Diabetes (Onset 9)

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 26 Oct 2018

At a glance

  • Drugs Insulin aspart (Primary) ; Insulin degludec (Primary) ; Metformin
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms onset9
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 24 Oct 2018 This trial has been completed in Germany.
    • 31 Aug 2018 Biomarkers information updated
    • 10 Jul 2018 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top